Arizona R&D Refundable Tax Credit

Arizona R&D Refundable Tax Credit

Provides Arizona innovators with refundable innovation tax credits to improve cash flow during product development.

Eligibility · United States · US-AZ

Arizona's R&D Refundable Tax Credit is a distinct, application-based program administered by the Arizona Commerce Authority (ACA) under A.R.S. §41-1507, layered on top of the standard nonrefundable R&D income tax credit administered by the Arizona Department of Revenue under A.R.S. §43-1168 (corporations) and §43-1074.01 (individuals). The nonrefundable credit, in effect since 1992, is calculated at 24% of the first $2.5 million in qualifying research expenses plus 15% of expenses above $2.5 million (rates applicable through tax year 2030; declining to 20%/11% in 2031 and beyond). The refundable component, established by SB 1254 in 2010, allows companies that have generated excess nonrefundable R&D credit — meaning the credit exceeds their current-year Arizona tax liability — to apply to the ACA for a partial cash refund of up to 75% of that excess amount.

Eligibility for the refundable component is restricted to companies with fewer than 150 full-time employees, making it specifically targeted at small and mid-stage R&D-intensive businesses that are unlikely to have sufficient Arizona tax liability to absorb large credit balances. The research must be conducted in Arizona and meet the qualifying research expense standards analogous to federal IRC §41. The refundable credit application is submitted to the ACA, not the Department of Revenue; upon ACA approval, the refund amount is processed through the Arizona tax return. An additional University R&D Tax Credit — equal to 10% of basic research payments exceeding the base amount made to universities under the jurisdiction of the Arizona Board of Regents — also requires ACA pre-certification before the Department of Revenue will process the credit.

For Arizona-based startup and growth-stage technology companies, the ACA-administered refundable component converts excess R&D credits into liquidity, functioning as a de facto non-dilutive funding mechanism. Companies in life sciences, aerospace, semiconductor, and software sectors have historically been the primary beneficiaries. The annual application to the ACA introduces a modest administrative step beyond the standard tax filing, but the economic benefit — recovering up to 75% of unused credit in cash — substantially outweighs the compliance cost for companies with significant Arizona R&D payrolls and limited current-year tax exposure.